+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), By Distribution Channel, And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 80 Pages
  • July 2025
  • Region: United States
  • Grand View Research
  • ID: 6154567
Description Jump to:
The U.S. acromegaly treatment market size was estimated at USD 571.3 million in 2024 and is projected to reach USD 977.2 million by 2033, growing at a CAGR of 6.2% from 2025 to 2033. This is attributed to the rising prevalence of acromegaly and earlier diagnoses, coupled with advancements in diagnostic tools such as MRI and IGF-1 tests, improved awareness, and a better understanding of the disease’s symptoms.

Technological advances in diagnostics and the adoption of personalized treatment regimens are expected to help early detection and adherence. Strong healthcare infrastructure, insurance support, and multidisciplinary care teams are further expected to support market expansion.

Moreover, advances in treatment options, including newer somatostatin analogs, growth hormone receptor antagonists, and personalized therapies, offer improved efficacy and fewer side effects. These innovations enhance patient outcomes and expand the treatment pool, fueling market demand and encouraging further investment in research and development.

U.S. Acromegaly Treatment Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. acromegaly treatment market report based on drug class, and distribution channel:

Drug Class Outlook (Revenue, USD Million, 2021 - 2033)

  • Somatostatin Analogues (SSAs)
  • Growth Hormone Receptor Antagonists (GHRAs)
  • Dopamine Agonists
  • Other Drug Types (Combination Therapies, Pipeline Drugs)

Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. Internal Database
1.3.3. Secondary Sources & Third-Party Perspectives
1.3.4. Primary Research
1.4. Information Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Acromegaly Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related Market Outlook
3.2. Industry Value Chain Analysis
3.3. Regulatory Framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.2. Market Restraint Analysis
3.4.3. Industry Challenges
3.4.4. Industry Opportunities
3.5. Industry Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.6. Market Entry Strategies
Chapter 4. Consumer Behavior Analysis
4.1. Demographic Analysis
4.2. Consumer Trends and Preferences
4.3. Factors Affecting Buying Decision
4.4. Consumer Drug Class Adoption
4.5. Observations & Recommendations
Chapter 5. U.S. Acromegaly Treatment Market: Drug Class Estimates & Trend Analysis
5.1. U.S. Acromegaly Treatment Market Drug Class: Key Takeaways
5.2. Drug Class Movement Analysis & Market Share, 2024 & 2033
5.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Drug Class, 2021 To 2033 (USD Million)
5.3.1. Somatostatin Analogues (SSAs)
5.3.1.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.2. Growth Hormone Receptor Antagonists (GHRAs)
5.3.2.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.3. Dopamine Agonists
5.3.3.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
5.3.4. Other Drug Types (Combination Therapies, Pipeline Drugs)
5.3.4.1. Market Estimates & Forecasts, 2021 To 2033 (USD Million)
Chapter 6. U.S. Acromegaly Treatment Market: Distribution Channel Estimates & Trend Analysis
6.1. U.S. Acromegaly Treatment Market Distribution Channel: Key Takeaways
6.2. Distribution Channel Movement Analysis & Market Share, 2024 & 2033
6.3. U.S. Acromegaly Treatment Market Estimates & Forecast, By Distribution Channel, 2021 to 2033 (USD Million)
6.3.1. Hospital Pharmacies
6.3.1.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
6.3.2. Retail Pharmacies
6.3.2.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
6.3.3. Others
6.3.3.1. Market Estimates & Forecasts, 2021 to 2033 (USD Million)
Chapter 7. U.S. Acromegaly Treatment Market - Competitive Landscape
7.1. Recent Developments & Impact Analysis by Key Market Participants
7.2. Company Heat Map/ Positioning Analysis
7.3. Strategy Mapping
7.4. Company Profiles
7.4.1. Novartis AG
7.4.1.1. Company Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Ipsen Pharma
7.4.2.1. Company Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Sun Pharmaceutical Industries Ltd
7.4.3.1. Company Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Chiasma, Inc.
7.4.4.1. Company Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Crinetics Pharmaceuticals
7.4.5.1. Company Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. WOCKHARDT
7.4.6.1. Company Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Pfizer Inc.
7.4.7.1. Company Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. Ionis Pharmaceuticals, Inc.
7.4.8.1. Company Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Teva Pharmaceuticals
7.4.9.1. Company Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
List of Tables
Table 1. U.S. Acromegaly Treatment Market Estimates And Forecast, By Drug Class, 2021 - 2033 (USD Million)
Table 2. U.S. Acromegaly Treatment Market Estimates And Forecast, By Distribution Channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 U.S. Acromegaly Treatment Market Segmentation
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Primary Research Approaches
Fig. 5 Primary Research Process
Fig. 6 Market Snapshot
Fig. 7 Drug Class Segment Snapshot
Fig. 8 Distribution Channel Segment Snapshot
Fig. 9 Competitive Landscape Snapshot
Fig. 10 U.S. Acromegaly Treatment Market Value, 2024 (USD Million)
Fig. 11 U.S. Acromegaly Treatment Market - Industry Value Chain Analysis
Fig. 12 U.S. Acromegaly Treatment Market Dynamics
Fig. 13 U.S. Acromegaly Treatment Market: Porter’s Analysis
Fig. 14 U.S. Acromegaly Treatment Market, By Drug Class: Key Takeaways
Fig. 15 U.S. Acromegaly Treatment Market, By Drug Class: Market Share, 2024 & 2033
Fig. 16 Somatostatin Analogues (SSAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 17 Growth Hormone Receptor Antagonists (GHRAs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 18 Dopamine Agonists Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 19 Other Drug Types (Combination Therapies, Pipeline Drugs) Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 20 U.S. Acromegaly Treatment Market, By Distribution Channel: Key Takeaways
Fig. 21 U.S. Acromegaly Treatment Market, By Distribution Channel: Market Share, 2024 & 2033
Fig. 22 Hospital Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 23 Retail Pharmacies Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 24 Others Market Estimates & Forecasts, 2021 - 2033 (USD Million)
Fig. 25 Key Company Categorization
Fig. 26 Strategic Framework

Companies Mentioned

  • Novartis AG
  • Ipsen Pharma
  • Sun Pharmaceutical Industries Ltd
  • Chiasma, Inc.
  • Crinetics Pharmaceuticals
  • WOCKHARDT
  • Pfizer Inc.
  • Ionis Pharmaceuticals, Inc.
  • Teva Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages80
PublishedJuly 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 571.3 Million
Forecasted Market Value ( USD ) by 2033 $ 977.2 Million
Compound Annual Growth Rate6.2%
Regions CoveredUnited States
No. of Companies Mentioned9

Related Topics

Related Reports

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogs, GHRA, Dopamine Agonists), By Distribution Channel (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Acromegaly Treatment Market Size, Share & Trends Analysis Report By Drug Class (Somatostatin Analogs, GHRA, Dopamine Agonists), By Distribution Channel (Hospitals & Clinics), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Acromegaly Treatment - Global Strategic Business Report - Product Image

Acromegaly Treatment - Global Strategic Business Report

  • Report
  • 297 Pages
  • Global
From
Acromegaly Market - A Global and Regional Analysis: Focus on Drug Class, and Regional Analysis - Analysis and Forecast, 2025-2035 - Product Image

Acromegaly Market - A Global and Regional Analysis: Focus on Drug Class, and Regional Analysis - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Acromegaly Treatment Market by Treatment Type (Combination Therapies, Dopamine Agonists, Growth Hormone Receptor Antagonists), Route Of Administration (Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030 - Product Image

Acromegaly Treatment Market by Treatment Type (Combination Therapies, Dopamine Agonists, Growth Hormone Receptor Antagonists), Route Of Administration (Injectable, Oral), Distribution Channel, End User - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
Acromegaly- Pipeline Insight, 2025 - Product Image

Acromegaly- Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From

About the Acromegaly Drug Market

The Acromegaly Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat acromegaly, a condition caused by an excess of growth hormone. These drugs are used to reduce the production of growth hormone, reduce its effects, or both. Commonly used drugs include somatostatin analogs, dopamine agonists, and GH receptor antagonists. Surgery is also an option for some patients. The Acromegaly Drug market is highly competitive, with many companies offering treatments. Some of the major players in the market include Novartis, Pfizer, Ipsen, and Teva Pharmaceuticals. Other companies include Sandoz, Merck, and Eli Lilly. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.